Confirming the Benefit of Dual Orexin-Receptor Antagonist TS-142 in Insomnia is the goal of the third phase of the study.

Published Date: 23 Apr 2023

A long-term study involving 300 patients with the sleeping disorder will evaluate Taisho Pharmaceutical's TS-142 after it showed promise in a phase 2 evaluation.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A BRAF V600E mutation-positive intrathoracic synovial sarcoma is reported by researchers.

2.

No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer

3.

Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.

4.

An inoperable locally advanced NSCLC trial dubbed "Practice Changing".

5.

CDC Alerts on Dramatic Rise in Human Parvovirus B19


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot